| Autor: |
Mendes VG; Clinical Research Laboratory in Chagas Disease Evandro Chagas National Institute of Infectious Diseases Rio de Janeiro Brazil., Rimolo L; Antonio Pedro University Hospital Fluminense Federal University Niterói Brazil., de Lima ACB; Molecular Biology and Endemic Diseases Laboratory Oswaldo Cruz Institute Rio de Janeiro Brazil., Ferreira RR; Laboratory of Applied Genomics and Bioinnovations Oswaldo Cruz Institute Rio de Janeiro Brazil., Oliveira LS; Clinical Research Laboratory in Chagas Disease Evandro Chagas National Institute of Infectious Diseases Rio de Janeiro Brazil., Nisimura LM; Laboratory of Innovations in Therapies, Education and Bioproducts Oswaldo Cruz Institute Rio de Janeiro Brazil., Horita SIM; Laboratory of Innovations in Therapies, Education and Bioproducts Oswaldo Cruz Institute Rio de Janeiro Brazil., Costa AR; Clinical Research Laboratory in Chagas Disease Evandro Chagas National Institute of Infectious Diseases Rio de Janeiro Brazil., da Silva GMS; Clinical Research Laboratory in Chagas Disease Evandro Chagas National Institute of Infectious Diseases Rio de Janeiro Brazil., Sangenis LHC; Clinical Research Laboratory in Chagas Disease Evandro Chagas National Institute of Infectious Diseases Rio de Janeiro Brazil., Mendes FSNS; Clinical Research Laboratory in Chagas Disease Evandro Chagas National Institute of Infectious Diseases Rio de Janeiro Brazil., Sousa AS; Clinical Research Laboratory in Chagas Disease Evandro Chagas National Institute of Infectious Diseases Rio de Janeiro Brazil., Veloso HH; Clinical Research Laboratory in Chagas Disease Evandro Chagas National Institute of Infectious Diseases Rio de Janeiro Brazil., Holanda MT; Clinical Research Laboratory in Chagas Disease Evandro Chagas National Institute of Infectious Diseases Rio de Janeiro Brazil., Mediano MFF; Clinical Research Laboratory in Chagas Disease Evandro Chagas National Institute of Infectious Diseases Rio de Janeiro Brazil., Waghabi MC; Laboratory of Applied Genomics and Bioinnovations Oswaldo Cruz Institute Rio de Janeiro Brazil., Garzoni LR; Laboratory of Innovations in Therapies, Education and Bioproducts Oswaldo Cruz Institute Rio de Janeiro Brazil., Moreira OC; Laboratory of Molecular Virology and Parasitology Oswaldo Cruz Institute Rio de Janeiro Brazil., Britto C; Molecular Biology and Endemic Diseases Laboratory Oswaldo Cruz Institute Rio de Janeiro Brazil., Cunha AB; Antonio Pedro University Hospital Fluminense Federal University Niterói Brazil., Hasslocher-Moreno AM; Clinical Research Laboratory in Chagas Disease Evandro Chagas National Institute of Infectious Diseases Rio de Janeiro Brazil., Saraiva RM; Clinical Research Laboratory in Chagas Disease Evandro Chagas National Institute of Infectious Diseases Rio de Janeiro Brazil. |
| Abstrakt: |
Background Chagas disease (CD) presents an ominous prognosis. The predictive value of biomarkers and new echocardiogram parameters in adjusted models have not been well studied. Methods and Results There were 361 patients with chronic CD (57.6% men, 61±11 years of age, clinical forms: indeterminate 27.1%, cardiac 56.6%, digestive 3.6%, cardiodigestive 12.7%) included in this single-center, observational, prospective longitudinal study. Echocardiographic evaluation included strain analyses of left atrial, left ventricular (LV), and right ventricular and 3-dimensional analyses of left atrial and LV volumes. Biomarkers included cardiac troponin I, brain natriuretic peptide, transforming growth factor β1, tumor necrosis factor, matrix metalloproteinases, and Trypanosoma cruzi polymerase chain reaction. The studied end point was a composite of CD-related mortality, heart transplant, hospital admission due to worsening heart failure, or new cardiac device insertion. Event-free survival was analyzed by multivariable regression analyses adjusted for competing risks. P values <0.05 were considered significant. The composite event occurred in 79 patients after 4.9±2.0 years follow-up. LV end-diastolic volume (hazard ratio [HR], 1.01 [95% CI, 1.00-1.02]; P =0.02), peak negative global atrial strain (HR, 1.08 [95% CI, 1.00-1.17]; P =0.04), LV global circumferential strain (HR, 1.12 [95% CI, 1.04-1.21]; P =0.003), LV torsion (HR, 0.55 [95% CI, 0.35-0.81]; P =0.003), brain natriuretic peptide (HR, 2.03 [95% CI, 1.23-3.34]; P =0.005), and positive T cruzi polymerase chain reaction (HR, 1.80 [95% CI, 1.12-2.91]; P =0.01) were end point predictors independent from age, sex, 2-dimensional echocardiographic indexes, hypertension, previous cardiac device, and CD cardiac form. Conclusions Two-dimensional strain- and 3-dimensional-derived parameters, brain natriuretic peptide, and positive T cruzi polymerase chain reaction can be useful for prediction of CD cardiovascular events. |
Plný text